MacroGenics Insider Action: Bonvini’s $2.60 Option Exercise Boosts Investor Confidence in Biologics Pipeline
MacroGenics insider activity: CEO Bonvini’s recent option exercise signals strong confidence in its autoimmune and oncology pipeline—what it means for investors.
3 minutes to read